Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 17/20 | 0.54 |
| ▸ | SELP | P16109 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13040208 | 0.90 | SELE (0.54) | SELESELP | |
| SCHEMBL13040184 | 0.89 | SELE (0.53) | SELESELP | |
| SCHEMBL13295107 | 0.88 | SELE (0.61) | SELESELP | |
| SCHEMBL15488911 | 0.88 | SELE (0.62) | SELESELP | |
| SCHEMBL14558013 | 0.87 | SELE (0.61) | SELESELP | |
| SCHEMBL13657266 | 0.85 | SELE (0.65) | SELESELP | |
| SCHEMBL19559698 | 0.84 | SELE (0.66) | SELESELP | |
| SCHEMBL15214014 | 0.84 | SELE (0.65) | SELESELP | |
| SCHEMBL14823276 | 0.84 | SELE (0.71) | SELESELP | |
| SCHEMBL13077121 | 0.84 | SELE (0.40) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184229-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8410066-B2 | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors | GLYCOMIMETICS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410066-B2 | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors | GLYCOMIMETICS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184229-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | SELE 3/4885SELP 12/4885 |
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | SELE 3/4885SELP 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.